Trial Profile

An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Gemcitabine
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms KEYLYNK-009
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

20 May 2024 Planned End Date changed from 20 Sep 2024 to 18 Nov 2025.
09 Dec 2023 Primary endpoint has not been met. (Overall Survival (OS))
09 Dec 2023 Primary endpoint has not been met. (Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1))

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com